- Conditions
- Acute Pancreatitis
- Interventions
- Dabigatran Etexilate Mesylate, Standard of Care
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 93
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- RSV Infection
- Interventions
- EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Long Beach, California • Berlin, New Jersey
- Conditions
- COVID-19
- Interventions
- ALG-097558, Dabigatran, Itraconazole, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,708 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Connecticut
- Conditions
- Healthy
- Interventions
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Atrial Fibrillation
- Interventions
- pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
- Conditions
- Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
- Interventions
- Dabigatran Etexilate Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute DVT of Lower Extremity
- Interventions
- Vascular Boot, Standard of Care
- Combination Product · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- warfarin, Dabigatran dose 1, Dabigatran dose 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 374
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
- Conditions
- Atrial Fibrillation, Medication Adherence
- Interventions
- Medication Education
- Other
- Lead sponsor
- Parkview Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- Atrial Fibrillation
- Interventions
- dabigatran with ASA, warfarin, dabigatran without ASA
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 14
- States / cities
- Fayetteville, Arkansas • La Mesa, California • Pensacola, Florida + 11 more
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • New Britain, Connecticut • Orlando, Florida + 13 more
- Conditions
- Coronary Artery Disease
- Interventions
- Dabigatran, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy Adult Participants
- Interventions
- BGB-43395, Midazolam, Celecoxib, Dabigatran etexilate, Rosuvastatin
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Atrial Fibrillation (AF), VTE
- Interventions
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Healthy
- Interventions
- Dabigatran, Bosutinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- DeLand, Florida
- Conditions
- Venous Thromboembolism
- Interventions
- Dabigatran, Warfarin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 5,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 1 Year to 2 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- Atrial Fibrillation
- Interventions
- Dabigatran etexilate (Pradaxa)
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah